The Possible Protective Role of Glucagon-like Peptide 1 on Endothelium During the Meal and Evidence for an "endothelial Resistance" to Glucagon-like Peptide 1 in Diabetes
Overview
Authors
Affiliations
Objective: Glucagon-like peptide 1 (GLP-1) stimulates insulin secretion. However, GLP-1 also improves endothelial function in diabetes.
Research Design And Methods: Sixteen type 2 diabetic patients and 12 control subjects received a meal, an oral glucose tolerance test (OGTT), and two hyperglycemic clamps, with or without GLP-1. The clamps were repeated in diabetic patients after 2 months of strict glycemic control.
Results: During the meal, glycemia, nitrotyrosine, and plasma 8-iso prostaglandin F2α (8-iso-PGF2a) remained unchanged in the control subjects, whereas they increased in diabetic patients. Flow-mediated vasodilation (FMD) decreased in diabetes, whereas GLP-1 increased in both groups. During the OGTT, an increase in glycemia, nitrotyrosine, and 8-iso-PGF2a and a decrease in FMD were observed at 1 h in the control subjects and at 1 and 2 h in the diabetic patients. In the same way, GLP-1 increased in both groups at the same levels of the meal. During the clamps, in both the control subjects and the diabetic patients, a significant increase in nitrotyrosine and 8-iso-PGF2a and a decrease in FMD were observed, effects that were significantly reduced by GLP-1. After improved glycemic control, hyperglycemia during the clamps was less effective in producing oxidative stress and endothelial dysfunction and the GLP-1 administration was most effective in reducing these effects.
Conclusions: Our data suggest that during the meal GLP-1 can simultaneously exert an incretin effect on insulin secretion and a protective effect on endothelial function, reasonably controlling oxidative stress generation. The ability of GLP-1 in protecting endothelial function seems to depend on the level of glycemia, a phenomenon already described for insulin secretion.
Skrobucha A, Pindlowski P, Krajewska N, Grabowski M, Jonik S Front Cardiovasc Med. 2025; 11:1446468.
PMID: 39741663 PMC: 11685754. DOI: 10.3389/fcvm.2024.1446468.
Taktaz F, Fontanella R, Scisciola L, Pesapane A, Basilicata M, Ghosh P Cardiovasc Diabetol. 2024; 23(1):242.
PMID: 38987789 PMC: 11238498. DOI: 10.1186/s12933-024-02319-7.
Akbari A, Hadizadeh S, Heidary L J Diabetes Res. 2024; 2024:3212795.
PMID: 38529046 PMC: 10963118. DOI: 10.1155/2024/3212795.
Dietary Fat Modulation of Gut Microbiota and Impact on Regulatory Pathways Controlling Food Intake.
Hamamah S, Amin A, Al-Kassir A, Chuang J, Covasa M Nutrients. 2023; 15(15).
PMID: 37571301 PMC: 10421457. DOI: 10.3390/nu15153365.
Gut Molecules in Cardiometabolic Diseases: The Mechanisms behind the Story.
Inceu A, Neag M, Craciun A, Buzoianu A Int J Mol Sci. 2023; 24(4).
PMID: 36834796 PMC: 9965280. DOI: 10.3390/ijms24043385.